Welcome to our dedicated page for Collplant Biotechnologies SEC filings (Ticker: CLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding CollPlant’s breakthrough in plant-based rhCollagen often means combing through pages of scientific jargon, clinical trial tables, and royalty schedules. If you have ever searched for "CollPlant SEC filings explained simply" or wondered how a single 8-K can shift expectations for its AbbVie collaboration, you know the challenge. Our SEC Filings hub eliminates this friction, delivering every document the moment it hits EDGAR and translating technical language into plain English.
Need the numbers fast? Our AI reads each "CollPlant quarterly earnings report 10-Q filing" and delivers revenue by product class, burn-rate trends, and milestone payments in seconds. It flags "CollPlant 8-K material events explained" so you never miss a clinical update, and it tracks "CollPlant Form 4 insider transactions real-time" to reveal executive sentiment. Whether you’re comparing cash runway in the "CollPlant annual report 10-K simplified," dissecting dilution risk inside a proxy, or scanning "CollPlant executive stock transactions Form 4," our platform surfaces what matters and stores the full text for deeper review.
Beyond raw documents, Stock Titan layers expert context: AI-powered summaries spotlight how bioink revenue growth shows up in segment notes, while footnote extractions clarify royalty obligations tied to the Stratasys deal. Real-time alerts on "CollPlant insider trading Form 4 transactions" help monitor confidence ahead of FDA milestones, and side-by-side visuals support "CollPlant earnings report filing analysis" without spreadsheets. From "understanding CollPlant SEC documents with AI" to pinpointing "CollPlant proxy statement executive compensation," investors gain a clear view of the company’s progress in regenerative medicine—without wading through 300 pages of disclosures.
CollPlant Biotechnologies filed a Form 6-K reporting it issued a press release titled “CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada.” The release is furnished as an exhibit to the report. The update highlights broader distribution coverage for the company’s rhCollagen across the U.S. and Canada.
CollPlant Biotechnologies (CLGN) filed a Form 6-K noting it issued a press release on October 16, 2025 titled “First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk.” The notice highlights Mayo Clinic researchers’ work and references CollPlant’s rhCollagen-based BioInk. No additional operational or financial details are included in this filing excerpt.
CollPlant Biotechnologies Ltd (CLGN) filed a Form 144 notifying a proposed sale of 140,000 ordinary shares through UBS Securities LLC with an aggregate market value of
The shares were acquired in a private placement from the issuer on
CollPlant Biotechnologies Ltd (CLGN) Schedule 13D shows members of the Loewenbaum family and related trusts collectively beneficially own 1,698,533 ordinary shares, representing 13.4% of outstanding shares based on 12,716,014 shares outstanding as of June 30, 2025. Individual holdings disclosed include George W. Loewenbaum with 1,256,056 shares (9.9%), Lillian S. Loewenbaum with 186,289 shares (1.5%), and several trusts and entities holding the remainder. Recent open-market purchases in late July 2025 at prices from $2.25 to $2.41 are reported. The stated purpose is investment; no present plans to effect corporate changes, but the group will continue to review its position. A Joint Filing Agreement governs the filing.
FAQ
What is the current stock price of Collplant Biotechnologies (CLGN)?
What is the market cap of Collplant Biotechnologies (CLGN)?
